Am J Psychiatry 1982; 139:1054-1056
Copyright © 1982 by American Psychiatric Association

REGULAR ARTICLES

RBC and plasma levels of haloperidol and clinical response in schizophrenia

RC Smith, G Vroulis, A Shvartsburd, R Allen, N Lewis, JC Schoolar, M Chojnacki and R Johnson

The authors conducted a fixed-dose study of haloperidol blood levels and clinical response in schizophrenic in patients and found that those with steady-state RBC haloperidol levels in the range of 2.4--5.4 ng/ml showed greater improvement than those with lower or higher levels. They found a similar , although nonsignificant, curvilinear relationship between plasma haloperidol levels and clinical response. These findings suggest that the relationship between haloperidol blood levels and clinical response fits a therapeutic window for the treatment of schizophrenia.

This article has been cited by other articles:

				F.W.A. Browne, S.J. Cooper, R. Wilson, and D.J. King Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients J Psychopharmacol, January 1, 1988; 2(2): 94 - 103. [Abstract] [PDF]

				R. J. Baldessarini, B. M. Cohen, and M. H. Teicher Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses Arch Gen Psychiatry, January 1, 1988; 45(1): 79 - 91. [Abstract] [PDF]

				R. C. Smith, R. Baumgartner, C. H. Misra, M. Mauldin, A. Shvartsburd, B. T. Ho, and C. DeJohn Haloperidol: Plasma Levels and Prolactin Response as Predictors of Clinical Improvement in Schizophrenia: Chemical v Radioreceptor Plasma Level Assays Arch Gen Psychiatry, November 1, 1984; 41(11): 1044 - 1049. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1982 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us